Today RQ BIO has announced a licencing agreement with AstraZeneca for its portfolio of early-stage monoclonal antibodies targeted against SARS-CoV-2, with the company also emerging from stealth mode on completion of the agreement. RQ Bio is a UK-based biotechnology company focused on developing treatments and preventative therapies based on potent broad-spectrum mAbs to address areas of unmet need in vulnerable patient populations.
Steve Bates OBE, Chief Executive of the BioIndustry Association and Chair of the International Council of Biotech Associations said “Now that the text is open to public scrutiny after its formal proposal by the WTO Director-General, it is clear that what is proposed would do nothing to solve any of the challenges we face in 2022 and will only make it far harder for small companies pioneering in this space to develop future innovative solutions.
The National Institute for Health and Care Excellence (NICE) has published draft guidance on the value of two antimicrobial drugs – Pfizer’s ceftazidime with avibactam and Shionogi’s cefiderocol – to the NHS, as part of a project to test a new subscription-style payment model for antimicrobials. NICE and its partners will now work to “review the approach taken in this project and develop routine arrangements for the evaluation and purchase of antimicrobials for the NHS.”
The UK is the place in the world where life science investment works hardest
UK biotech companies continue to demonstrate they command the confidence of global venture capital (VC) investors with £453m raised in the first quarter of 2022, new data published by the BioIndustry Association (BIA) and Clarivate shows. The first quarter is the best for UK biotech VC financing ever recorded by BIA and Clarivate and neither the US nor China enjoyed the same year on year growth.
Catalent have announced this morning that they have acquired the Vaccine Manufacturing Innovation Centre, in Harwell Oxford.
Steve Bates OBE, Chief Executive of the BioIndustry Association (BIA) and former member of the Vaccine Taskforce (2020) said:
“I welcome Catalent’s purchase of the VMIC facility, they have the track record of, and ability to, invest further in the site and team for years to come. Through this process a significant US manufacturer has been brought into the UK bioprocessing ecosystem.
Steve Bates OBE, Chief Executive of the BioIndustry Association (BIA) and former member of the Vaccine taskforce (2020) said: “The UK has been at the forefront of the global response to the COVID-19 pandemic, developing and manufacturing vaccines required to end global lockdowns. The acceleration of mRNA technology has been astonishing during the pandemic and it is now set to be a significant industrial opportunity. The Government's investment will increase a vital part of the mRNA supply chain here in the UK and will lead to an expansion at the Croda facility, creating jobs and investment in the Staffordshire area.
Steve Bates OBE, Chief Executive of the BioIndustry Association said: “The UK biotech and life sciences sector is well prepared to be a partner to deliver fast growth in the UK for the benefit of patients and taxpayers.
New ‘Shared Commitments’ set out priority actions for genomics initiatives across the UK
Cancer diagnosis, earlier detection of diseases and patient access to clinical trials will improve
Plans will advance government’s priorities to reform healthcare and make the UK a scientific superpower
Patients across the UK are set to benefit from faster cancer diagnosis and innovative new treatments thanks to a ground-breaking agreement with the nation’s devolved governments.
This World Kidney Day, our charity partner, Kidney Research UK, is spreading awareness to show the impact of kidney disease on patients and families and to help the public to better understand why kidneys matter. Get to know your kidneys better and use an online kidney health check. Take part in the BIA 850 Global Challenge for Kidney Research UK.